Immunitybio Stock Probability of Future Stock Price Finishing Over 20.0

IBRX Stock  USD 4.91  0.33  6.30%   
Immunitybio's implied volatility is one of the determining factors in the pricing options written on Immunitybio. Implied volatility approximates the future value of Immunitybio based on the option's current value. Options with high implied volatility have higher premiums and can be used to hedge the downside of investing in Immunitybio over a specific time period. For example, 2024-04-19 CALL at $5.0 is a CALL option contract on Immunitybio's common stock with a strick price of 5.0 expiring on 2024-04-19. The contract was last traded on 2024-04-18 at 15:59:10 for $0.35 and, as of today, has 0 days remaining before the expiration. The option is currently trading at a bid price of $0.25, and an ask price of $0.35. The implied volatility as of the 19th of April is 383.33. View All Immunitybio options

Closest to current price Immunitybio long CALL Option Payoff at Expiration

Immunitybio's future price is the expected price of Immunitybio instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Immunitybio performance during a given time horizon utilizing its historical volatility. Check out Immunitybio Backtesting, Immunitybio Valuation, Immunitybio Correlation, Immunitybio Hype Analysis, Immunitybio Volatility, Immunitybio History as well as Immunitybio Performance.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.
  
Price To Sales Ratio is likely to drop to 3,900 in 2024. Price Earnings Ratio is likely to drop to -4.6 in 2024. Please specify Immunitybio's target price for which you would like Immunitybio odds to be computed.

Immunitybio Target Price Odds to finish over 20.0

The tendency of Immunitybio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 20.00  or more in 90 days
 4.91 90 days 20.00 
close to zero percent
Based on a normal probability distribution, the odds of Immunitybio to move over $ 20.00  or more in 90 days from now is close to zero percent (This Immunitybio probability density function shows the probability of Immunitybio Stock to fall within a particular range of prices over 90 days) . Probability of Immunitybio price to stay between its current price of $ 4.91  and $ 20.00  at the end of the 90-day period is about 42.36 .
Given the investment horizon of 90 days the stock has the beta coefficient of 4.87 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Immunitybio will likely underperform. Additionally Immunitybio has an alpha of 0.4032, implying that it can generate a 0.4 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
   Immunitybio Price Density   
       Price  

Predictive Modules for Immunitybio

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunitybio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunitybio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.265.1712.81
Details
Intrinsic
Valuation
LowRealHigh
0.214.3011.94
Details
Naive
Forecast
LowNextHigh
0.094.5412.18
Details
2 Analysts
Consensus
LowTargetHigh
4.104.505.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immunitybio. Your research has to be compared to or analyzed against Immunitybio's peers to derive any actionable benefits. When done correctly, Immunitybio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Immunitybio.

Immunitybio Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunitybio is not an exception. The market had few large corrections towards the Immunitybio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunitybio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunitybio within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
0.40
β
Beta against NYSE Composite4.87
σ
Overall volatility
0.83
Ir
Information ratio 0.08

Immunitybio Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunitybio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunitybio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Immunitybio is way too risky over 90 days horizon
Immunitybio appears to be risky and price may revert if volatility continues
Immunitybio has high likelihood to experience some financial distress in the next 2 years
The company currently holds 883.68 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immunitybio until it has trouble settling it off, either with new capital or with free cash flow. So, Immunitybio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immunitybio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immunitybio to invest in growth at high rates of return. When we think about Immunitybio's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 622 K. Net Loss for the year was (583.2 M) with profit before overhead, payroll, taxes, and interest of 240 K.
Immunitybio currently holds about 82.94 M in cash with (366.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21.
Immunitybio has a frail financial position based on the latest SEC disclosures
Roughly 80.0% of the company shares are held by company insiders
Latest headline from seekingalpha.com: ImmunityBio files automatic mixed shelf

Immunitybio Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunitybio Stock often depends not only on the future outlook of the current and potential Immunitybio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunitybio's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding508.6 M
Cash And Short Term Investments266.5 M

Immunitybio Technical Analysis

Immunitybio's future price can be derived by breaking down and analyzing its technical indicators over time. Immunitybio Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Immunitybio. In general, you should focus on analyzing Immunitybio Stock price patterns and their correlations with different microeconomic environments and drivers.

Immunitybio Predictive Forecast Models

Immunitybio's time-series forecasting models is one of many Immunitybio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Immunitybio's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Immunitybio

Checking the ongoing alerts about Immunitybio for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immunitybio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Immunitybio is way too risky over 90 days horizon
Immunitybio appears to be risky and price may revert if volatility continues
Immunitybio has high likelihood to experience some financial distress in the next 2 years
The company currently holds 883.68 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immunitybio until it has trouble settling it off, either with new capital or with free cash flow. So, Immunitybio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immunitybio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immunitybio to invest in growth at high rates of return. When we think about Immunitybio's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 622 K. Net Loss for the year was (583.2 M) with profit before overhead, payroll, taxes, and interest of 240 K.
Immunitybio currently holds about 82.94 M in cash with (366.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21.
Immunitybio has a frail financial position based on the latest SEC disclosures
Roughly 80.0% of the company shares are held by company insiders
Latest headline from seekingalpha.com: ImmunityBio files automatic mixed shelf
When determining whether Immunitybio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunitybio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunitybio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunitybio Stock:
Check out Immunitybio Backtesting, Immunitybio Valuation, Immunitybio Correlation, Immunitybio Hype Analysis, Immunitybio Volatility, Immunitybio History as well as Immunitybio Performance.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Immunitybio Stock analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is Immunitybio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.15)
Revenue Per Share
0.001
Quarterly Revenue Growth
0.904
Return On Assets
(0.52)
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.